MoonLake Immunotherapeutics Reports 2025 Financials, Updates on SLK Clinical Pipeline, and Loan Facility Amendment

summarizeSummary

MoonLake Immunotherapeutics reported increased net losses in 2025 but extended its cash runway into H2 2027 through a public offering, despite missing certain loan milestones. The company continues to advance its promising SLK clinical pipeline with positive trial results and regulatory progress.

check_boxKey Events

• Full Year 2025 Financial Results

  The company reported a net loss of $230.3 million for the year ended December 31, 2025, a significant increase from $121.2 million in 2024, driven by higher research and development and general and administrative expenses.

• Extended Cash Runway

  As of December 31, 2025, MoonLake had $394.0 million in cash, cash equivalents, and short-term marketable securities, projected to fund operations into the second half of 2027.

• Loan Facility Milestones Missed and Amended

  MoonLake failed to meet Tranche 2 and 4 milestones for its $500 million Hercules Capital loan facility due to a higher-than-expected placebo response in the VELA-2 trial, reducing committed funds by $175 million. A subsequent amendment on February 20, 2026, allowed for a $25 million draw from the second tranche, with up to $400 million remaining available.

• 2025 Public Offering Completed

  In November 2025, the company completed a public offering of 7,142,857 Class A Ordinary Shares at $10.50 per share, generating net proceeds of $72.4 million.

auto_awesomeAnalysis

MoonLake Immunotherapeutics' annual report provides a comprehensive overview of its financial performance and clinical pipeline. The company reported a significant increase in net loss to $230.3 million in 2025, up from $121.2 million in 2024, reflecting increased R&D and G&A expenses as it advances its lead asset, SLK. Despite the widening loss, the company maintains a cash runway into the second half of 2027, supported by a $72.4 million public offering in November 2025. A notable financial event was the failure to meet Tranche 2 and 4 milestones for its Hercules Capital loan, which reduced committed funds by $175 million. However, a subsequent amendment to the loan agreement allowed for an additional $25 million draw, with $400 million remaining available. The filing also reiterates strong clinical progress for SLK across multiple indications, including positive Phase 3 data in HS, FDA Fast Track designation for PPP, and positive Phase 2 results in axSpA. An ongoing class action lawsuit and a new 10b5-1 trading plan by the CFO to sell a notable amount of shares are also disclosed.